Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.

Patoulias D, Popovic DS, Stoian AP, Janez A, Sahebkar A, Rizzo M

Journal of diabetes and its complications7 Jun 2023Cited by 29 (Europe PMC)

PMID37301063DOI10.1016/j.jdiacomp.2023.108529PepBankPUB-37301063

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced HbA1c more than other GLP-1 receptor agonists in head-to-head trials.
In plain wordsIn pooled head-to-head trials in type 2 diabetes, semaglutide lowered HbA1c more than other GLP-1 drugs.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c reduction
0.44%
semaglutide vs other GLP-1RAs
Source sentences
Summary
Semaglutide compared to other GLP-1RAs provided a significantly greater reduction in HbA1c levels by 0.44 %, in fasting plasma glucose by 0.48 mmol/L, in body weight by 2.53 kg and in body mass index by 0.91 kg/m².
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106301
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced fasting plasma glucose more than other GLP-1 receptor agonists in head-to-head trials.
In plain wordsIn pooled head-to-head trials in type 2 diabetes, semaglutide lowered fasting blood glucose more than other GLP-1 drugs.
Peptide
Semaglutide
Outcome
DecreaseFasting plasma glucose reduction
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
fasting plasma glucose reduction
0.48 mmol/L
semaglutide vs other GLP-1RAs
Source sentences
Summary
Semaglutide compared to other GLP-1RAs provided a significantly greater reduction in HbA1c levels by 0.44 %, in fasting plasma glucose by 0.48 mmol/L, in body weight by 2.53 kg and in body mass index by 0.91 kg/m².
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106302
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced body weight more than other GLP-1 receptor agonists in head-to-head trials.
In plain wordsIn pooled head-to-head trials in type 2 diabetes, semaglutide led to more weight loss than other GLP-1 drugs.
Peptide
Semaglutide
Outcome
DecreaseBody weight reduction
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
body weight reduction
2.53 kg
semaglutide vs other GLP-1RAs
Source sentences
Summary
Semaglutide compared to other GLP-1RAs provided a significantly greater reduction in HbA1c levels by 0.44 %, in fasting plasma glucose by 0.48 mmol/L, in body weight by 2.53 kg and in body mass index by 0.91 kg/m².
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106303
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced body mass index more than other GLP-1 receptor agonists in head-to-head trials.
In plain wordsIn pooled head-to-head trials in type 2 diabetes, semaglutide lowered body mass index more than other GLP-1 drugs.
Peptide
Semaglutide
Outcome
DecreaseBody mass index reduction
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
BMI reduction
0.91 kg/m2
semaglutide vs other GLP-1RAs
Source sentences
Summary
Semaglutide compared to other GLP-1RAs provided a significantly greater reduction in HbA1c levels by 0.44 %, in fasting plasma glucose by 0.48 mmol/L, in body weight by 2.53 kg and in body mass index by 0.91 kg/m².
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106304
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide gave greater odds of reaching target HbA1c than other GLP-1 receptor agonists.
In plain wordsIn pooled head-to-head trials in type 2 diabetes, people on semaglutide were more likely to reach their HbA1c target than with other GLP-1 drugs.
Peptide
Semaglutide
Outcome
IncreaseAchieving target HbA1c
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subjects receiving semaglutide experienced significantly greater odds for achieving target and optimal HbA1c, along with significantly greater odds for weight loss >5 % and 10 %.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106305
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide gave greater odds of reaching optimal HbA1c than other GLP-1 receptor agonists.
In plain wordsIn pooled head-to-head trials in type 2 diabetes, people on semaglutide were more likely to reach an optimal HbA1c than with other GLP-1 drugs.
Peptide
Semaglutide
Outcome
IncreaseAchieving optimal HbA1c
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subjects receiving semaglutide experienced significantly greater odds for achieving target and optimal HbA1c, along with significantly greater odds for weight loss >5 % and 10 %.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106306
07HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide gave greater odds of weight loss above 5 % than other GLP-1 receptor agonists.
In plain wordsIn head-to-head trials in type 2 diabetes, people on semaglutide were likelier to lose over 5 % of weight than with other GLP-1 drugs.
Peptide
Semaglutide
Outcome
IncreaseWeight loss greater than 5 %
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subjects receiving semaglutide experienced significantly greater odds for achieving target and optimal HbA1c, along with significantly greater odds for weight loss >5 % and 10 %.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106307
08HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide gave greater odds of weight loss above 10 % than other GLP-1 receptor agonists.
In plain wordsIn head-to-head trials in type 2 diabetes, people on semaglutide were likelier to lose over 10 % of weight than with other GLP-1 drugs.
Peptide
Semaglutide
Outcome
IncreaseWeight loss greater than 10 %
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subjects receiving semaglutide experienced significantly greater odds for achieving target and optimal HbA1c, along with significantly greater odds for weight loss >5 % and 10 %.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106308
09HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, semaglutide gave greater odds of gastrointestinal adverse events than other GLP-1 receptor agonists.
In plain wordsIn pooled head-to-head trials in type 2 diabetes, digestive side effects were more likely with semaglutide than with other GLP-1 drugs.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
However, subjects randomized to semaglutide also experienced significantly greater odds for gastrointestinal adverse events and treatment discontinuation.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106309
10HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, semaglutide gave greater odds of treatment discontinuation than other GLP-1 receptor agonists.
In plain wordsIn pooled head-to-head trials in type 2 diabetes, people were more likely to stop semaglutide than other GLP-1 drugs.
Peptide
Semaglutide
Outcome
IncreaseTreatment discontinuation
Study
n = 3,760
Comparator
Other GLP-1 receptor agonists
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
However, subjects randomized to semaglutide also experienced significantly greater odds for gastrointestinal adverse events and treatment discontinuation.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed and Cochrane Library databases, along with grey literature sources, were searched form inception to 8th February 2023, in order to retrieve head-to-head, phase 3 randomized controlled trials (RCTs) assessing the effect of semaglutide versus other GLP-1RAs on glycemia and other cardio-metaboli…
Report a problemFND-3730106310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.